These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 33454584

  • 1. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.
    DeLuca J, Schippling S, Montalban X, Kappos L, Cree BAC, Comi G, Arnold DL, Hartung HP, Sheffield JK, Liu H, Silva D, Cohen JA.
    Mult Scler Relat Disord; 2021 Feb; 48():102673. PubMed ID: 33454584
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, SUNBEAM Study Investigators.
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, RADIANCE Trial Investigators.
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [Abstract] [Full Text] [Related]

  • 4. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
    Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, Southworth H, Kappos L, Cohen JA, Ozanimod Study Investigators.
    Eur J Neurol; 2021 Nov; 28(11):3722-3730. PubMed ID: 34292643
    [Abstract] [Full Text] [Related]

  • 5. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
    Benedict RH, Cohan S, Lynch SG, Riester K, Wang P, Castro-Borrero W, Elkins J, Sabatella G.
    Mult Scler; 2018 May; 24(6):795-804. PubMed ID: 28485186
    [Abstract] [Full Text] [Related]

  • 6. Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
    Selmaj KW, Cohen JA, Comi G, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Havrdova EK, Cree BAC, Minton N, Sheffield JK, Ding N, Kappos L.
    Mult Scler Relat Disord; 2021 Jun; 51():102844. PubMed ID: 33892317
    [Abstract] [Full Text] [Related]

  • 7. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
    Rasche L, Paul F.
    Expert Opin Pharmacother; 2018 Dec; 19(18):2073-2086. PubMed ID: 30407868
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW, RADIANCE Study Group.
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [Abstract] [Full Text] [Related]

  • 9. Phase III SUNBEAM and RADIANCE PART B trials for Ozanimod in relapsing multiple sclerosis demonstrate superiority versus interferon-β-1a (Avonex®) in reducing annualized relapse rates and MRI brain lesions.
    Koscielny V.
    Neurodegener Dis Manag; 2018 Jun; 8(3):141-142. PubMed ID: 29943693
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L, RADIANCE Trial Investigators.
    Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
    [Abstract] [Full Text] [Related]

  • 11. Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis.
    Nie T, Syed YY.
    CNS Drugs; 2024 Nov; 38(11):931-941. PubMed ID: 39368032
    [Abstract] [Full Text] [Related]

  • 12. Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results.
    Wilken J, Traboulsee A, Nelson F, Ionete C, Kolind S, Fratto T, Kane R, Gandhi R, Rawlings AM, Roesch N, Ozog MA, DeLuca J, LEM-COG investigators.
    Mult Scler Relat Disord; 2023 May; 73():104677. PubMed ID: 37028124
    [Abstract] [Full Text] [Related]

  • 13. Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons.
    Jiang T, Shanmugasundaram M, Božin I, Freedman MS, Lewin JB, Shen C, Ziemssen T, Arnold DL.
    J Comp Eff Res; 2024 Oct; 13(10):e230161. PubMed ID: 39158844
    [Abstract] [Full Text] [Related]

  • 14. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S, Kumar J, Arndorfer S, Zhu X, Zivkovic M, Tencer T.
    CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
    [Abstract] [Full Text] [Related]

  • 15. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
    Liu Y, Vollmer T, Havrdova E, Riester K, Lee A, Phillips G, Wang P, Sabatella G.
    Mult Scler Relat Disord; 2017 Jan; 11():18-24. PubMed ID: 28104250
    [Abstract] [Full Text] [Related]

  • 16. Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset.
    Castrogiovanni N, Mostert J, Repovic P, Bowen JD, Uitdehaag BMJ, Strijbis EMM, Cutter GR, Koch MW.
    Neurology; 2023 Jul 04; 101(1):e1-e11. PubMed ID: 37072219
    [Abstract] [Full Text] [Related]

  • 17. Association between symbol digit modalities test and regional cortex thickness in young adults with relapsing-remitting multiple sclerosis.
    Tao Y, XueSong Z, Xiao Y, YueZhi K, Xin W, YanPing T, Lei W, YongPing F.
    Clin Neurol Neurosurg; 2021 Aug 04; 207():106805. PubMed ID: 34280674
    [Abstract] [Full Text] [Related]

  • 18. Ozanimod: First Approval.
    Lamb YN.
    Drugs; 2020 Jun 04; 80(8):841-848. PubMed ID: 32385738
    [Abstract] [Full Text] [Related]

  • 19. Ozanimod for the treatment of relapsing forms of multiple sclerosis.
    Kuczynski AM, Oh J.
    Neurodegener Dis Manag; 2021 Jun 04; 11(3):207-220. PubMed ID: 34011158
    [Abstract] [Full Text] [Related]

  • 20. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
    Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L, Hashmonay R, Agashivala N, McCague K, Tenenbaum N, Edwards K.
    BMC Neurol; 2014 Nov 26; 14():220. PubMed ID: 25424122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.